Deadline extended: Survey on understanding the gaps in SACT education to minority group cancer patients

The deadline to respond to the survey has been extended to Friday 15th December.

The aim of the wider project is to develop recommendations of areas that should be incorporated into pharmacy staff teaching. I would be very grateful if you could complete this questionnaire to understand the gaps that exist when educating a patient from a minority group, receiving systemic anticancer therapy (SACT). 

If you have any questions about this project then please email me via: [email protected]

It should take 10-15minutes to complete. All responses will be anonymous.

https://forms.office.com/e/CwQwB45j0Z

 

Many thanks for your participation!

Apini Patel

Senior Oncology Pharmacist 

Latest News

By BOPA Executive Committee on 4th November 2025

Joint BOPA and PASG Position Statement Safer Handling of Hazardous SACT Drugs: A Pharmacy Workforce Position Statement

BOPA and PASG Publish Joint Position Statement on the Safer Handling of Hazardous SACT Drugs The British Oncology Pharmacy Association (BOPA) and the NHS Pharmaceutical Aseptic Services Group (PASG) have…

Read article
By Jennifer Allen - LCC Lead on 4th November 2025

BOPA’s Let’s Communicate Cancer (LCC) series receives re-accreditation from the Royal Society for Public Health (RSPH)

The Let’s Communicate Cancer (LCC) series, available for free on the BOPA website CancerHUB: Home Page – BOPA, has recently received re-accreditation from the Royal Society for Public Health which…

Read article
By BOPA Executive Committee on 3rd November 2025

BOPA’s Submission for the National Cancer Plan for England 2025 – Call for Evidence

With the National Cancer Plan 2025 for England Publication imminent (Shaping the national cancer plan – GOV.UK) – please find BOPA’s Submission for the call for evidence below: BOPA Submission…

Read article
By BOPA IOSIG on 1st November 2025

IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events

  IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events Have your say on a critical issue affecting immunotherapy patients across the UK. The IOCN and UKSACT Board have…

Read article